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Abstract
Background: Diabetes mellitus is a public health challenge worldwide, and roughly 25 % of patients with diabetes
in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated
foot is amputation, leading to premature death and larger economic costs.
Methods: This study aimed to estimate the economic costs of diabetic foot in high-risk patients in Peru in 2012 and to
model the cost-effectiveness of a year-long preventive strategy for foot ulceration including: sub-optimal care (baseline),
standard care as recommended by the International Diabetes Federation, and standard care plus daily self-monitoring of
foot temperature. A decision tree model using a population prevalence-based approach was used to calculate the costs
and the incremental cost-effectiveness ratio (ICER). Outcome measures were deaths and major amputations, uncertainty
was tested with a one-way sensitivity analysis.
Results: The direct costs for prevention and management with sub-optimal care for high-risk diabetics is around
US$74.5 million dollars in a single year, which decreases to US$71.8 million for standard care and increases to
US$96.8 million for standard care plus temperature monitoring. The implementation of a standard care strategy
would avert 791 deaths and is cost-saving in comparison to sub-optimal care. For standard care plus temperature
monitoring compared to sub-optimal care the ICER rises to US$16,124 per death averted and averts 1,385 deaths.
Conclusion: Diabetic foot complications are highly costly and largely preventable in Peru. The implementation of a
standard care strategy would lead to net savings and avert deaths over a one-year period. More intensive prevention
strategies such as incorporating temperature monitoring may also be cost-effective.
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Diabetes mellitus
Background
Diabetes mellitus is a chronic disease that presents a
challenge for health care systems worldwide. One major
complication of diabetes mellitus is the development of
diabetic foot [1, 2], which may be costly for families,
health systems and society. In developing countries 25 %
of diabetic patients develop at least one foot ulcer during
their lifetime [3, 4] as a result of delays in diabetes
diagnosis, poor access to health care and poor treatment
adherence [5].
Diabetic foot is characterized by retardation and death
of peripheral nervous tissue in the foot, which results in
susceptibility to ulcerative infection. Over time, the gravest
outcome from ulcerated feet is amputation, which may
also be accompanied by pain, disability, risk of depression
and decreased quality of life [3].
In 2005, the International Diabetes Federation (IDF)
recommended yearly foot check-ups for all patients with
diabetes in order to identify those at high-risk of ulceration
[6]. In Peru, 30 % of people with diabetes were unaware of
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their condition [7] and only 8 % of patients undergoing
treatment met control targets [7].
The objective of this analysis is to estimate the cost-of-
illness (COI) attributable to diabetic foot in the patients at
high-risk of ulceration in Peru for different secondary pre-
vention strategies. A cost-effectiveness analysis is also con-
ducted. We consider three strategies: sub-optimal care or
usual care in Peru (used as comparator), standard care
based on IDF recommendations, and an intensive strategy
based on standard care plus temperature monitoring.
Methods
i) Design
A COI study was developed following an
ingredients-based approach where unit costs for
resources are multiplied by the quantity used. A
decision tree model (see Fig. 1) was constructed to
show cases of patients at high-risk of ulceration,
diabetic foot and related outcomes. A population
prevalence-based approach was performed to
illustrate the costs and benefits that can be
achieved in the first year of each strategy. All
sources for key parameters are listed in Table 1.
ii) Definition of prevention strategies
The sub-optimal care or baseline situation was
assumed to include an annual visit to a physician
and podiatrist where routine tests are performed
once, but neither education nor appropriate footwear
is provided.
The second strategy, called standard care, was
based on IDF guidelines [6], which emphasizes
attention by a cadre of medical professionals,
bi-monthly consultations, a higher frequency of
tests, podiatrist consultation with foot evaluation,
education and use of insoles (see Table 2).
Thirdly, a standard care plus temperature
monitoring strategy was included, which added daily
self-monitoring of foot temperature to the standard
care. This involves the use of a handheld
thermometer for recording and monitoring
fluctuations in foot temperature of individuals.
If patients find a high degree of fluctuation in
temperature between both feet, higher or equal
to 2.2 °C, they need to call a nurse and schedule a
consultation. This strategy has been applied in a
number of clinical trials yielding consistent positive
results [8–10].
iii) Epidemiology
Our calculations considered the Peruvian adult
population (18–79 years old) with Type 2 diabetes
mellitus who were at high-risk of developing diabetic
foot ulcer due to severe neuropathy with foot
deformity or a history of ulceration. We used
the IDF national data for the prevalence of
Type 2 diabetes in Peru, estimated at 5.38 % in
year 2011 [11]. This resulted in nearly 942,000
people having the disease. The prevalence of
being at high-risk for diabetic foot was defined
as the prevalence rate of severe neuropathy
among diabetic patients, assumed to be 21.9 %
based on previous studies for developing countries
[12, 13]. It was calculated that the population in
Peru with severe neuropathy was 206,298 persons.
We have excluded patients with peripheral ischemia
from our approach given that this population was
also excluded in clinical trial studies exploring
temperature monitoring as a preventative strategy
for diabetic foot [8–10].
The three different prevention strategies affected a
reduction in the one-year ulceration rate for those
that were at high-risk for diabetic foot. To illustrate
Fig. 1 Decision tree diagram for patients at high-risk of ulceration, diabetic foot and related outcomes
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the achievable health benefits, it was assumed that
each strategy was introduced at scale. For the
sub-optimal care strategy as baseline, the ulceration
prevalence rate was assumed to be 22.18 %. This
figure came from considering the ulceration
prevalence rate for the standard care in a clinical
trial study reported as 12.2 % [9], together with an
effectiveness estimations of 45 % derived from the
United States Center for Disease Control and Pre-
vention (CDC) [14, 15] when moving from a
Table 1 Epidemiology and cost inputs
Parameter Value Lower estimate Upper estimate Reference
Epidemiology
a. Total population with Type 2 diabetes
mellitus
942,000 [11]
b. % diabetics at high risk for ulcer 21.90 % [12, 13]
c. Prevalence of ulcer in those at high-risk 22.18 % 15.53 % 28.84 % [9, 14, 15] Own assumption: values for lower
and upper estimate +/−30 %
c1. Effectiveness (reduced prevalence) with
standard care
45.00 % 30.00 % 60.00 % [9, 14, 15] Own assumption: assumed values
for lower and upper estimate.
c2. Effectiveness (reduced prevalence) with
standard care plus temperature
monitoring
78.81 % 65.00 % 85.00 % [9, 14, 15] Own assumption: assumed values
for lower and upper estimate.
d. % with ulcer receiving hospital care 30.00 % 21.00 % 39.00 % [16] Own assumption: values for lower and
upper estimate +/−30 %
e. % with ulcer receiving outpatient wound
management
70.00 % 61.00 % 79.00 % [16] Own assumption: values for lower and
upper estimate.
f. % at hospital with amputation and heal 47.75 % 33.43 % 62.08 % [16] Own assumption: values for lower and
upper estimate +/−30 %
f1. % with major amputation 55.80 % [16]
f2. % with minor amputation 44.20 % [16]
g. % at hospital with debridement and heal 39.45 % 25.12 % 53.77 % [16] Own assumption: values for lower and
upper estimate +/−30 %
h. % at hospital that die of diabetic foot
after an amputation
12.80 % [16]
Direct costs (in 2012 US dollars)
Prevention
Sub-optimal care 65 45 84 [17, 18] Other local prices. Own assumption:
values for lower and upper estimate
+/−30 %
Standard care 185 129 240 [17, 18] Other local prices. Own assumption:
values for lower and upper estimate
+/−30 %
Standard care plus temperature monitoring 406 285 528 [17, 18] Other local prices. Own assumption:





79 [17, 18] Other local prices.
Debridement 1,022 [17, 18] Other local prices.
Minor amputation 5,153 [17, 18] Other local prices.
Major amputation 7,360 5,152 9,568 [17, 18] Other local prices. Own assumption:
values for lower and upper estimate
+/−30 %
Indirect costs (in 2012 US dollars)
Productivity loss from premature death 6,719 Peru's basic salary in year 2012; 3 %
discount rate.
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scenario of sub-optimal care to standard care. An
even higher reduction of 79 % in the baseline rate of
ulceration is achieved with the standard care plus
temperature monitoring, achieving a 4.7 % of
ulceration rate [9].
iv) Clinical outcomes
We determined the likely clinical outcomes for
different scenarios. The data was for a one-year period
related to diabetic foot treatment and complications
such as ulcer development, wound management,
debridement procedure, amputation and death.
We considered the parameters from a Brazilian
study [16] that provides rates for hospitalization
and outcomes attributed to diabetic foot ulceration
in patients attended by the public health system.
This kind of study has not been implemented in
Peru and there is a lack of reliable epidemiological
data from the health statistics at hospitals. In the
Brazilian COI study [16], 70 % of ulcerated patients
heal without hospitalization, and therefore, we
assumed that those patients only receive outpatient
wound management. The other 30 % of patients
require hospitalization, with 39.5 % healing with
primary care (assumed as debridement procedure),
47.8 % healing by a minor or major amputation, and
12.8 % dying after amputation surgery. Our
assumption here is that all patients who die had an
amputation in the same year. Among those patients
who undertook amputation surgery in the Brazilian
study, 44.2 % received a minor amputation and
55.8 % a major amputation. Table 1 shows the
values used and assumptions made for this study.
v) Cost data
Direct costs of resources used to prevent or
manage the disease were registered under a
societal perspective. We identified the main
medical procedures that can be carried out in Peru
related to each stage of diabetic foot. We followed
an ingredients-based approach for our costing
analysis (see Additional file 1). We estimated the
number of specific procedures, personnel, medical
supplies, examinations and medications for each
disease stage according to the IDF guidelines. The
unit costs of treatment were taken from a list
of tariffs in a public hospital of the Ministry of
Health in Peru [17]. We considered generic
drug prices [18].
Costs were registered at the local currency
Peruvian Nuevos Soles (PEN) and converted to US
dollars (US$), considering an average exchange
rate of 2.64 PEN per dollar in year 2012 [19].
Additionally, the indirect costs due to premature
death were measured using a human capital
approach. Minimum wage rate in Peru amounts to
US$284 in year 2012. We assumed a monthly
income equal to minimum wage and a mean age
of 63 years for premature mortality, according to
the primary data of patients with neuropathy in a
public hospital in Lima [12]. We considered that
two years, with a retirement age of 65, of paid
productive work were lost due to the death and
discounted at an annual rate of 3 %.
Table 2 Major assumptions in cost-of-illness estimation
A. Wound management without hospitalization
Outpatient: 1 first visit, 2 visits of control, 3 minor healing procedures in
a hospital. Test: HbA1C, lipid profile, X-ray. Medication: Clindamycin
300 mg qid for 2 weeks.
B. Debridement
Inpatient: Emergency consultation, 6 days of hospitalization, evaluation
by anesthesiologist and cardiologist, anesthesiology medication and
surgical materials, debridement procedure, intermediate care unit and 6
wound healing procedures. Test: Pre-surgery tests, antibiogram, HbA1C,
lipid profile and X-ray. Medication: Intravenous antibiotic (Ampicillin/
Sulbactam 1.5 g qid for 3 days), oral antibiotics for 11 days and peripheral
line. Outpatient: Consultations with physician until healed at the hospital
and materials for dressing changes.
C. Amputation
Inpatient: Emergency consultation, 10 days (minor amputation) or 19 days
(major amputation) of hospitalization, evaluation by anesthesiologist and
cardiologist, anesthesiology medication and surgical materials, amputation
procedure, intermediate care unit and blood transfusion. Test: Pre-surgery
tests, bacteriology study, HbA1C, lipid profile, white cells count, X-ray,
Doppler echography, arteriography, MRI, tissue biopsy. Medication:
Intravenous antibiotic (Ampicillin/Sulbactam 1.5 g qid for 3 days in minor
amputation and 5 days in major amputation), oral antibiotics (11 days in
minor and 16 days in major amputation) and peripheral line. Outpatient:
Consultations with physician and podiatrist until healed, materials for
dressing changes (assuming that a nurse or a trained person at home is in
charge of this procedure). Others: Rehabilitation sessions (40 for minor
amputation and 50 for major amputation), orthopedic supplies for foot
amputation (crutches and orthopedic foot) or for leg amputation (crutches,
orthopedic leg, wheelchair), caregiver at home (conservative assumption of
6 months at Peru´s basic salary or 12 months working partial time).
D. Premature death
We assumed that 2 years (retirement age of 65) of paid productive work
were lost due to the death and discounted at an annual rate of 3 %.
Minimum wage rate in Peru amounts to PEN 750 in year 2012 (equivalent
to US$284). We assumed a monthly income equal to minimum wage. The
estimated indirect cost was US$6,719, which is the net value of the lost
earnings for the next 2 years.
E. Sub-optimal care
Outpatient: 1 annual consultation with physician and podiatrist. Test: 1
annual testing of HbA1C, lipid profile, creatinine, electrocardiogram, X-ray.
F. Standard care
Outpatient: 6 consultations with physicians, 1 consultation with the
podiatrist and 1 education session with a nurse. Test: 3 annual
evaluations of HbA1C, 1 annual testing of lipid profile, 2 creatinine tests,
2 electrodiagrams and 1 X-ray. Others: protective footwear (a pair).
G. Standard care plus temperature monitoring
Similar to standard care, but in addition: thermometer and daily phone
calls assisted by a nurse or a trained person (about 5 minutes per
patient everyday).
HbA1C glycosylated hemoglobin, MRI magnetic resonance imaging
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vi) Cost-effectiveness analysis
Cost-effectiveness is examined in terms of cost per
deaths averted. The analysis consisted in estimating
the incremental cost-effectiveness ratio (ICER) by
estimating the additional costs and deaths averted
for each of the preventive strategies compared to
the sub-optimal strategy. Since the analysis only
looked at costs and effects for one-year, there was
no discounting.
vii) Sensitivity analysis
We conducted multiple one-way sensitivity analysis
to assess the uncertainty of the key input parameters.
The variables of interest were independently varied
according to their plausible range from Table 1.
Most of the variables were varied using a range
of +/− 30 %, given that uncertainty ranges were
not available in the literature. The resulting
change in cost-effectiveness was then taken and the
variables were ordered in a tornado diagram from
the most to the least sensitive parameter.
viii) Key assumptions
The model assumed that healthcare utilization is
100 % and constant for the entire population.
Finally, our approach does not discriminate by
rural–urban setting, assuming that all patients
attend urban hospitals.
Ethics
We did not submit this study for ethics committee review
as no human subjects were involved in this research
study. We used aggregated and de-identified secondary
information from public domain sources.
Results
Direct costs of prevention and treatment of diabetic foot
ulcer in year 2012 varied depending on the different
strategies (see Table 3). The total COI, using only direct
costs for the three strategies adding preventive and treat-
ment costs was US$74,470,803 for sub-optimal care,
US$71,745,988 for standard care and US$96,800,267 for
standard care plus temperature monitoring. Standard
care strategy generates savings of roughly US$2.7 million
compared to sub-optimal care. Switching to the standard
care plus temperature monitoring strategy adds add-
itional cost to the sub-optimal strategy of approximately
US$22 million.
Figure 2 shows the COI results by category of re-
sources used. For sub-optimal and standard care, the
major cost drivers are inpatient visits, outpatient visits,
laboratory tests and other supplies. With standard care
plus temperature monitoring, these costs are greatly re-
duced due to a larger reduction in the number of ulcer-
ations, but the high cost of the thermometer device
plays a significant role.
Table 4 provides the total outcomes averted and cost-
effectiveness estimates for the strategies. In the baseline
sub-optimal strategy, our model gives that there will be
1,757 deaths resulting from foot ulceration (using a 22.18 %
prevalence rate). The standard care will avert 791 of these
deaths (using a 12.2 % prevalence rate) and the standard
Table 3 Cost of illness (direct costs) attributed to diabetic foot (2012 US dollars)
Description All strategies Sub-optimal care Standard care Standard care plus temperature
monitoring
Prevention strategy
Cost per person US$65 US$185 US$406
Total people 206,298 206,298 206,298
Total cost of prevention US$13,350,763 US$38,129,966 US$83,849,832
Complications Cost/person No. of people Total cost No. of people Total cost No. of people Total cost
Hospital
Healing with debridement US$1,022 5416 US$5,535,166 2979 US$3,044,341 1148 US$1,172,820
Healing with major amputation US$7,360 3658 US$26,921,264 2012 US$14,806,695 775 US$5,704,219
Healing with minor amputation US$5,153 2897 US$14,930,136 1594 US$8,211,575 614 US$3,163,476
Death with major amputation US$7,360 981 US$7,216,590 539 US$3,969,125 208 US$1,529,089
Death with minor amputation US$5,153 777 US$4,002,215 427 US$2,201,218 165 US$848,010
Subtotal US$26,048 13728 US$58,605,371 7551 US$32,232,954 2909 US$12,417,613
Outpatient
Healing with outpatient visit US$79 32032 US$2,514,669 17618 US$1,383,068 6787 US$532,821
Total No. of people/Total cost
of treatment
45761 US$61,120,040 25168 US$33,616,022 9696 US$12,950,435
Total cost US$74,470,803 US$71,745,988 US$96,800,267
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care plus temperature monitoring strategy will avert 1,385
of the total deaths (using a 4.7 % prevalence rate). In terms
of the health system burden, the standard care strategy will
avert 2,087 major amputations compared to the sub-
optimal care strategy, and standard care plus temperature
monitoring will prevent 3,656 major amputations com-
pared to the sub-optimal care strategy (see Table 4).
The ICER for standard care versus the sub-optimal
care is negative because of the cost-savings and is thus
a highly favored outcome. The ICER for standard care
plus temperature monitoring versus sub-optimal care
indicates that US$16,124 dollars need to be spent for
each additional death averted. The estimated indirect
cost was US$6,719, which is the net value of the lost
earnings for the next two years. When adding the indir-
ect costs, the ICER for standard care plus temperature
monitoring versus sub-optimal care becomes even
more favorable, at US$9,405 per death averted. When
comparing standard care plus temperature monitoring
versus standard care, the ICER is over US$35,000 per
death averted.
At the current baseline estimate, the ICERs are either
cost-saving or around US$16,000 per death averted for
standard care and standard care plus temperature moni-
toring compared to sub-optimal care. Figure 3a and b
show the results of a deterministic sensitivity analysis for
these findings. The most sensitive variable in each case
is the cost of the preventative strategy, which at a higher
value, makes the ICER of standard care and standard
care plus temperature monitoring less favorable. For the
standard care option, the effectiveness of ulcer reduction
by standard care, baseline ulcer prevalence and hospital
utilization are the next most important variables. For
standard care plus temperature monitoring, the second
and third most sensitive parameters are baseline ulcer
prevalence and hospital utilization, while the effectiveness
of ulcer reduction was the fourth most sensitive variable.
Discussion
Main findings
Diabetic foot prevention and management certainly result
in high economic burden for the Peruvian health system
Fig. 2 Resource usage for treatment and prevention of diabetic foot and related complications
Table 4 Outcomes and cost-effectiveness of secondary prevention for diabetic foot
Comparison Standard care vs.
sub-optimal care
Standard care plus temperature
monitoring vs. sub-optimal care
Standard care plus temperature
monitoring vs. standard care
Differences in costs (Δ costs)
Direct costs -US$2,724,815 US$22,329,464 US$25,054,279
Direct costs + Indirect costs -US$8,037,824 US$13,024,440 US$21,062,264
Differences in deaths (Δ deaths) 791 1,385 594
Differences in major amputations 2,087 3,656 1,568
Incremental cost-effectiveness ratio
(Δ costs/Δ deaths)
Direct costs Cost-saving ICER = 16,124 ICER = 42,169
Direct costs + Indirect costs Cost-saving ICER = 9,405 ICER = 35,450
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and society as well. The overall COI for prevention and
complications management with standard care strategy
would amount to a total savings of roughly US$2.7 million
and avert 791 deaths. Our findings suggest that secondary
prevention strategies are cost-effective for the individuals
and the government of Peru if properly implemented. We
note that ICER values per disability adjusted life year
(DALY) are usually compared with three times the Gross
Domestic Product (GDP) per capita of a country, which for
Peru was US$6,568 in 2012 [20]. Our ICER using deaths
averted is potentially more conservative given that disability
benefits are not accounted for. ICER fell under three times
the GDP per capita (US$16,124), we are confident it would
be considered cost-effective [21].
Furthermore, standard care alone is even cost-saving,
i.e. total costs decrease and deaths averted increase in
comparison to sub-optimal care. When adding the indir-
ect costs of lost productivity, the ICER for standard care
versus sub-optimal care remains cost-saving and the
standard care plus temperature monitoring versus sub-
optimal care becomes more favorable, at US$9,405 per
death averted. The sensitivity analysis showed that for the
standard care only, the ICERs still fell under three times
the GDP after varying the key parameters by +/−30 %.
From this analysis, a preventative strategy such as
standard care not only improves the current level of care,
but also leads to economic benefits in terms of societal
cost-savings. Since prevention must be provided to a
large number of patients at high-risk of ulceration, total
costs of the prevention strategies are high; however, in
the case of standard care plus temperature monitoring,
the costs of thermometers would decline over time after
the initial investment. For this strategy, even if the cost of
the thermometer was zero, the strategy of standard care
plus temperature monitoring would be cost-effective but
not cost-saving. In the future, temperature monitoring
technology may be integrated with electronic and mobile
health prevention platforms that could further reduce the
costs of personnel and phone services and make the
intervention even more attractive.
Comparison with the literature
Direct annual costs per patient calculated for management
of foot ulcers and other diabetic foot complications are
Fig. 3 a Tornado diagram for standard care vs. sub-optimal care. b Tornado diagram for standard care plus temperature monitoring vs. sub-optimal care
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lower in Peru than costs estimated in other studies for
developed countries [22–25]. Ulcers that require amputa-
tion can cost, per admission, from US$15,790 [26, 27] to
as high as US$45,870 [23, 27]. In contrast, a study in
Brazil [16] used a hypothetical cohort including all the
Brazilian citizens with Type 2 diabetes and estimated a
total annual cost of hospital admissions per patient start-
ing from US$2,151.
The reported costs of diabetic foot prevention and treat-
ment in developing and developed nations are difficult to
compare, further emphasizing the importance of studies
such as ours. Previous studies in cost-effective interventions
to prevent and control diabetes agree with our estimates
that comprehensive and multidisciplinary foot care leads to
cost-savings [28–33]. One systematic review [28] included
two studies that dealt with diabetic foot prevention, and
one of these studies used an optimal care strategy similar to
our standard care strategy [32]. An intensive prevention
strategy including patient education, foot care and footwear
was found to be cost-saving if the risk for foot ulcers and
lower extremity amputations were reduced by 25 % [32]
among those patients at risk of ulceration. In our study we
assumed a reduction of ulceration rate of 45 % in line with
lower bound estimates shown by the Centers for Disease
Control and Prevention for potential reductions in
amputation as a result of comprehensive foot care
program [14, 15]. A retrospective cohort study from
Austria using a Markov model, compared a dedicated
screening program with conventional preventive care
and concluded that the screening program would reduce
costs by 29.8 % for mild ulcers and by 49.7 % for severe
ulcers, primarily due to lower amputation rates [34].
Ollendorf et al. [35] estimated an increasing economic
benefit associated to educational interventions, multidis-
ciplinary teams, and the therapeutic shoe coverage. They
did not, however, include the costs of the underlying inter-
vention strategies.
Recent published studies indicate that the use of
temperature monitoring is an effective way to prevent
diabetic foot ulceration; however the cost-effectiveness
of temperature monitoring had not been yet studied
[29, 30]. Our study provides relevant findings about the
potential of standard care plus temperature monitoring
as a cost-effective prevention strategy even in a short-
term horizon. However, standard care as recommended
by the IDF is still more cost-effective and provides net
savings for the society.
Limitations
This study was performed from a societal perspective
considering all direct healthcare costs, regardless of who
paid; however, we did not include more assumptions
about travel costs and waiting time given the lack of
reliable information for those estimates. In this study, we
tried to be as conservative as possible when considering
the most appropriate health outcome indicator or whether
to include indirect costs into the analysis. We have only
considered productivity losses as indirect cost calculated
under the "human capital" approach. This approach gener-
ates large estimates, but we presented our results of the
ICER both including and excluding the productivity costs.
For the purpose of this cost-effectiveness study, we chose
two tangible outcomes as health effect indicators: amputa-
tions and deaths. Further cost-utility analysis may extend
this to looking at a summary health outcome that incor-
porates morbidity such as the quality adjusted life year
(QALY) or DALY. The estimates in this study are also
limited by the lack of available data on clinical outcomes
of preventative strategies specific to diabetic foot in Peru.
As a result, we at times used secondary information from
other country settings while aiming to use data from
developing countries.
Another limitation is the model assumption that health-
care utilization was 100 % and constant for the entire
population. We considered this assumption given the se-
vere condition of these kinds of patients and given the
lack of information on this issue. However, we expect that
a lower utilization rate would lead to more major compli-
cations and more fatal outcomes of those who do not re-
ceive timely medical care.
We also assume that the parameters apply for the whole
country and do not make a distinction between rural and
urban populations. It is likely that this decision contrib-
utes to an underestimation of the total COI because the
rural population will most likely incur larger indirect costs
due to travel and time to reach a hospital in urban area.
Our study calculated an ulcer rate using the data from a
clinical study that occurred over an 18-month period [9],
because longitudinal data is not yet available.
We only investigated the secondary prevention methods
for diabetic foot, and given the lack of data for the burden
of Type 1 diabetes, we did not include a comprehensive
overhaul of diabetes monitoring and prevention in order
to not overestimate and attribute costs that are also re-
lated with other complications (retinopathy, kidney dis-
eases, among others). We chose to provide a detailed
breakdown of costs, yearly costs, and unit costs, each pre-
sented separately. To ensure the wide applicability of our
study, we have offered a breakdown of the likely routes for
resource allocation in a given year. We are aware that
there are intangible benefits for the patients and their fam-
ilies that are impossible to measure in monetary terms.
We also only looked at the economic burden of the dis-
ease for the first year assuming that each prevention strat-
egy achieved full scale-up.
While aiming to produce a conservative estimate of the
cost of ulceration and amputation, we left out the added
risk for recurrent ulcers and new amputations, which could
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be included in the future development of a probabilistic
Markov model.
Implications and further research
Diabetes prevalence in Peru is rising [36] and there is a low
level of disease awareness and control [7]. Thus monitoring
and treatment protocols are urgently needed. The health
and economic impacts of diabetic foot are exacerbated in
Peru because of insufficient preventative measures. We
recommend validating costs and collecting better epi-
demiological data for diabetic foot disease in Peru.
Conclusion
We have provided an economic evaluation for tracing
costs related to prevention methods of diabetic foot
disease in a developing country. Our study found a cost-
saving result and decreased mortality associated with
adherence to the standard care as recommended by the
IDF relative to the current sub-optimal care that is pro-
vided in Peru. Additionally, we found that standard care
plus temperature monitoring was a promising cost-
effective strategy and could be even more cost-effective
with declining price in the thermometer device. Our re-
sults highlight the important economic impact on savings
and lives saved that diabetic foot programs can yield.
Additional file
Additional file 1: Cost estimates of procedures and preventative
strategies using the ingredients-based approach (Peru, 2012).
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